Incannex Healthcare Inc. (NASDAQ:IXHL) saw its stock jump 10% on Friday after positive Phase 2 trial results for its ...

Exit interviews and clinical results reinforce strong potential for meaningful improvements in sleep quality, cognitive function, and daily lifeMELBOURNE, Australia and NEW YORK, Aug. 08, 2025 (GLOBE ...

Incannex Healthcare Inc. (NASDAQ:IXHL) shares jumped 10% after the company announced encouraging Phase 2 trial results for ...

Incannex Healthcare (IXHL) stock falls even as the company's lead asset IHL-42X achieves success in a Phase 2 trial for sleep ...

Investing.com -- Incannex Healthcare Inc. (NASDAQ: IXHL) stock jumped 10% Friday following the release of positive Phase 2 trial results for its obstructive sleep apnea (OSA) treatment, IHL-42X.

Incannex Healthcare Issues Q1 Quarterly Update Clinical stage pharmaceutical development company, Incannex Healthcare Inc. (IXHL), (‘Incannex’ or the ‘Company’), is pleased to ...

Incannex's IHL-42X showed significant efficacy in Phase 2 sleep apnea trial, with strong AHI reduction, improved sleep, and ...

MELBOURNE, Australia, May 02, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company ...

Incannex anticipates greatly improved treatment compliance and outcomes from a pharmaceutical product, such as IHL-42X, subject to further clinical assessment and approval from regulators.

--Incannex Healthcare Inc.,, a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today announced that it has entered into security purchase ...

Incannex Healthcare Limited IXHLIHLcompleted a pre-investigational new drug application ('pre-IND') meeting with the U.S. Food and Drug Administration to discuss the development IHL-42X.

--Incannex Healthcare Limited, a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs ...